Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2024)

Innate Pharma (IPHA) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $9.8 million in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Deferred Tax Liability fell 6.74% year-over-year to $9.8 million; the trailing twelve-month figure through Jun 2024 stood at $9.8 million (down 6.74% YoY), and the FY2023 full-year result was $9.7 million, up 10.85% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2024 stood at $9.8 million, up from $9.7 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $1.3 billion in Q2 2020 and bottomed at $5.8 million in Q4 2021.
• The 5-year median for Non-Current Deferred Tax Liability is $8.7 million (2022), against an average of $148.5 million.
• The widest annual swing landed in 2020, when Non-Current Deferred Tax Liability soared 493.61%; it then plunged 99.49% in 2021.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $8.4 million in 2020, then plunged by 31.93% to $5.8 million in 2021, then soared by 51.98% to $8.7 million in 2022, then increased by 10.85% to $9.7 million in 2023, then rose by 1.39% to $9.8 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $9.8 million (Q2 2024), $9.7 million (Q4 2023), and $10.5 million (Q2 2023), per Business Quant data.

Peer Comparison